MarketPulse

earnings guidance

47 articles
BenzingaBenzinga··Vandana Singh

Charles River Labs to Divest CDMO and Discovery Units in Strategic Restructuring

Charles River Labs divests CDMO and discovery units to GI Partners and IQVIA, reducing revenue but boosting profitability and raising 2026 earnings guidance.
CRLIQVearnings guidancedivestiture
The Motley FoolThe Motley Fool··Keith Noonan

Duolingo Shares Lose Over One-Third of Value Amid Growth Strategy Shift

Duolingo stock plummeted 38% year-to-date after weak Q4 guidance and the company's shift to prioritize user growth over revenue, sparking investor concerns about near-term performance.
DUOLstock declineearnings guidance
The Motley FoolThe Motley Fool··Daniel Sparks

Salesforce Valuation Concerns Persist Despite Strong AI Momentum

Salesforce shows strong AI growth and cash flow, but high valuation multiples and elevated stock compensation amid slowing revenue growth raise shareholder value concerns.
GOOGGOOGLCRMearnings guidancefree cash flow
Investing.comInvesting.com··Thomas Hughes

DoorDash Stock Gains Momentum as Analysts Target 20-40% Upside on 2026 Outlook

DoorDash gains momentum with analysts targeting 20-40% upside on strong 2026 outlook. Q4 results show 40% revenue growth and 51% net income increase year-over-year.
DASHearnings guidancerevenue growth
Investing.comInvesting.com··Chris Markoch

Republic Services to Pursue $1B in M&A Despite Cash Flow Constraints

Republic Services plans $1B in acquisitions despite weak cash flow and modest 2026 growth guidance, raising investor concerns about financial flexibility.
RSGWMearnings guidancecapital expenditures
The Motley FoolThe Motley Fool··Daniel Sparks

Roku Reports Earnings Beat, but Valuation Concerns Persist

Roku beat earnings expectations and surged 8.45%, returning to profitability with strong 2026 outlook. However, analysts question its 40x valuation amid intensifying streaming competition.
ROKUearnings guidancevaluation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ANI Pharmaceuticals to Report 2025 Results, Reaffirms Guidance Expectations

ANI Pharmaceuticals will report 2025 results on February 27, 2026, reaffirming confidence in meeting or exceeding guidance for revenues, EBITDA, and earnings per share.
ANIPfinancial resultsearnings guidance